Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

May 16, 2023

SELL
$3.75 - $7.39 $136,875 - $269,735
-36,500 Closed
0 $0
Q1 2022

Apr 21, 2022

SELL
$4.07 - $10.6 $24,013 - $62,540
-5,900 Reduced 13.92%
36,500 $177,000
Q4 2021

Feb 03, 2022

SELL
$8.96 - $16.31 $69,888 - $127,217
-7,800 Reduced 15.54%
42,400 $424,000
Q3 2021

Oct 21, 2021

BUY
$11.24 - $21.0 $53,952 - $100,800
4,800 Added 10.57%
50,200 $959,000
Q2 2021

Aug 13, 2021

BUY
$18.04 - $22.09 $25,256 - $30,926
1,400 Added 3.18%
45,400 $1.45 Million
Q1 2021

Apr 30, 2021

BUY
$16.59 - $33.89 $350,049 - $715,079
21,100 Added 92.14%
44,000 $1.33 Million
Q4 2020

Feb 16, 2021

BUY
$27.5 - $37.92 $198,000 - $273,024
7,200 Added 45.86%
22,900 $991,000
Q3 2020

Nov 12, 2020

BUY
$34.44 - $43.75 $303,072 - $385,000
8,800 Added 127.54%
15,700 $847,000
Q2 2020

Aug 12, 2020

BUY
$27.12 - $45.97 $8,136 - $13,791
300 Added 4.55%
6,900 $421,000
Q1 2020

May 12, 2020

SELL
$26.16 - $63.5 $10,464 - $25,400
-400 Reduced 5.71%
6,600 $303,000
Q4 2019

Jan 27, 2020

BUY
$46.96 - $61.67 $136,184 - $178,843
2,900 Added 70.73%
7,000 $614,000
Q3 2019

Oct 22, 2019

SELL
$59.47 - $93.1 $41,629 - $65,169
-700 Reduced 14.58%
4,100 $376,000
Q2 2019

Jul 26, 2019

SELL
$75.84 - $105.21 $68,256 - $94,689
-900 Reduced 15.79%
4,800 $611,000
Q1 2019

Apr 25, 2019

BUY
$64.44 - $104.11 $90,216 - $145,754
1,400 Added 32.56%
5,700 $897,000
Q4 2018

Feb 07, 2019

SELL
$59.1 - $93.26 $17,730 - $27,978
-300 Reduced 6.52%
4,300 $427,000
Q3 2018

Nov 02, 2018

SELL
$88.86 - $117.49 $44,430 - $58,745
-500 Reduced 9.8%
4,600 $672,000
Q2 2018

Aug 03, 2018

BUY
$99.64 - $127.59 $508,164 - $650,709
5,100 New
5,100 $800,000

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $24.7M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Virginia Retirement Systems Et Al Portfolio

Follow Virginia Retirement Systems Et Al and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Virginia Retirement Systems Et Al with notifications on news.